More Stories

Informist, Thursday, Oct. 30, 2025

 

Please click here to read all liners published on this story

--Cipla: Expect gRevlimid to have small contribution to US revenue in Oct-Dec 
--Cipla: Upcoming launches to alleviate gRevlimid revenue fall over four qtrs
--Cipla: Launched 6 new pdts across therapies in One Africa during Apr-Sept
--Cipla: N America ops saw continuous traction in key differentiated assets
--Cipla: Expect to launch 3 peptide assets including Liraglutide in 2026
--Cipla: Expect to launch gAdvair in North America in Jan-Mar
--Cipla: Expect to launch 4 major respiratory assets in N America in 2026
--Cipla Jul-Sept One India sales INR 31.46 bln, up 7% on year
--Cipla Q2 consol research, development expense INR 5.39 bln, 7.1% of sales
--Cipla Jul-Sept North America sales $233 mln vs $237 mln year ago
--Cipla Jul-Sept Emerging Markets, Europe sales $110 mln, up 15% on year
--Cipla Jul-Sept One Africa sales $134 mln, up 5% on year
--Cipla Jul-Sept consol EBITDA INR 18.95 bln, up 0.5% on year
--Cipla Q2 consol new ventures sales INR 3.51 bln vs INR 3.20 bln yr ago
--Cipla Jul-Sept consol pharma revenue INR 72.91 bln vs INR 67.76 bln yr ago
--Cipla Apr-Sept consol revenue INR 145.47 bln vs INR 137.45 bln year ago
--Cipla Apr-Sept consol net profit INR 26.49 bln vs INR 24.80 bln year ago
--Cipla Jul-Sept consol revenue INR 75.89 bln vs INR 70.51 bln year ago
--Cipla Jul-Sept consol net profit INR 13.51 bln vs INR 13.03 bln year ago
--Analysts saw Cipla Jul-Sept consol revenue at INR 74.25 bln
--Cipla Jul-Sept consol revenue INR 75.89 bln
--Analysts saw Cipla Jul-Sept consol net profit at INR 13.92 bln
--Cipla Jul-Sept consol net profit INR 13.51 bln
 

 

By Narayana Krishna

 

HYDERABAD - Hit by weak sales in the US, Cipla Ltd. has reported only 4% on-year growth in its consolidated net profit to INR 13.5 billion for the September quarter, missing the analysts' estimates. Analysts had projected the drug major's net profit at 13.9 billion for Jul-Sept. Cipla's on-year net profit growth for the September quarter is the slowest in 13 quarters.

 

The company's revenue for the quarter was up 7.6% on year at INR 75.9 billion, above the analysts' average estimates of INR 74.25 billion. The company's North America sales slightly declined to $233 million from $237 million a year ago, resulting in marginal growth in the earnings before interest, tax, depreciation and amortisation. Cipla reported a 0.5% on-year growth in its September quarter consolidated EBITDA to INR 18.95 billion.

 

After the company announced its September quarter earnings, Cipla shares fell more and at 1354 IST, they traded 2.3% lower at INR 1,544.50 on the National Stock Exchange.  

 

NORTH AMERICA

As projected by analysts, the US generic sales saw a 1.7% on-year decline due to a fall in sales of cancer drug generic Revlimid. However, growth in sales of other drugs such as hormones treatment drug Lanreotide and asthma drug Albuterol helped the company to limit the fall in revenue growth. North America, mainly led by the US, contributed 27% of the total sales for the quarter. Cipla said the company is seeing continuous traction in key differentiated products.

 

"In Q3 FY26 (Oct-Dec), gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to US FDA (US Food and Drug Administration) approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized," Cipla said in a press release quoting Umang Vohra, chief executive officer and managing director, as saying.

 

The company expects to launch three peptide-based products, including Liraglutide, in North America, in 2026. Cipla is also planning to launch generic of Advair in the US during the March quarter. This drug is used to treat obstructive pulmonary disease. The company is aiming to launch four respiratory products in 2026, which would drive future growth.

 

INDIA & OTHER MARKETS

On the domestic front, Cipla reported 7% on-year growth in sales to INR 31.46 billion for the quarter. One India segment accounted for 41% of the total sales. Cipla's asthma inhaler Foracort emerged as the number one brand in the category, helping the company's respiratory portfolio growth for the September quarter. Cipla classified its India business as "One India" for its prescription, trade generics, consumer health, and institutional segments under one reporting category, to improve coordination and efficiency. 

 

The company's One Africa segment saw 5% on-year sales growth for the September quarter to $134 million, driven by new launches. Cipla launched six new products across therapies in the One Africa region in the six months ended September. "One Africa" combines its South African unit, Cipla Medpro, with other African markets to operate as one integrated business and drive growth across the region. This segment accounted for 16% of the total sales.

 

Cipla reported its emerging markets and Europe sales at $110 million, up 15% on year, led by new launches and traction in business-to-business category.

 

Besides weak US sales, the increased costs also impacted Cipla's September quarter margin performance. The company's research and development spending was INR 5.39 billion in Jul-Sept, accounting for 7.1% of total sales. The company's total expenses rose over 10% on year to INR 60 billion. Other expenses for the quarter were up 12.4% on year at INR 18.8 billion in Jul-Sept. Input costs for the quarter were up 3.7% on year at INR 15.3 billion.

 

The company's consolidated pharma operations revenue for the quarter stood at INR 72.91 billion for the latest quarter, while new venture sales were at INR 3.51 billion. For Apr-Sept, Cipla's consolidated net profit was up nearly 7% on year at INR 26.5 billion on revenue of INR 145.5 billion, which rose 6% on year.  End

 

US$1 = INR 88.70

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.